Icariside II induces apoptosis of melanoma cells through the downregulation of survival pathways

Nutrition and Cancer

Volumn 65, Issue 1, 2013, Pages 110-117

  Wu, Jinfeng ^a   Xu, Jinhua ^a   Eksioglu, Erika A ^b   Chen, Xianghong ^b   Zhou, Junmin ^b   Fortenbery, Nicole ^b   Wei, Sheng ^b   Dong, Jingcheng ^a  

^a FUDAN UNIVERSITY   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FLAVONOID GLYCOSIDE; ICARISIDE II; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CALIPER; CANCER CELL; CANCER SIZE; CELL ASSAY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HERBA EPIDEMIII; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLAVONOIDS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

MUS;

EID: 84873716005     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.741745     Document Type: Article

References (38)

1. Rigel DS, Russak J, Friedman R: The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 60, 301-316, 2010.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27, 6199-6206, 2009.
3. Sun W and Schuchter LM:Metastatic melanoma. Curr Treat Options Oncol 2, 193-202, 2001.
4. Katipamula R and Markovic SN: Emerging therapies for melanoma. Expert Rev Anticancer Ther 8, 553-560, 2008.
5. Eggermont AM: Advances in systemic treatment of melanoma. Ann Oncol 21(Suppl 7), 339-344, 2010.
6. Sekulic A, Haluska P, Jr., Miller AJ, Genebriera De Lamo J, Ejadi S, et al.: Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 83, 825-846, 2008.
7. Yu H and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4, 97-105, 2004.
8. Huang S: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 13, 1362-1366, 2007.
9. Buettner R, Mora LB, and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8, 945-954, 2002.
10. Darnell JE: Validating Stat3 in cancer therapy. Nat Med 11, 595-596, 2005.
11. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, et al.: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11, 1314-1321, 2005.
12. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, et al.: Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59, 5059-5063, 1999.
13. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al.: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115, 1999.
14. Eisenmann KM, Van Brocklin MW, Staffend NA, Kitchen SM, and Koo HM: Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 63, 8330-8337, 2003.
15. Koo HM, Van Brocklin M, McWilliams MJ, Leppla SH, Duesbery NS, et al.: Apoptosis andmelanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A 99, 3052-3057, 2002.
16. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, et al.: Apoptosis induction in human melanoma cells by inhibition of MEK is caspaseindependent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 13, 4934-4942, 2007.
17. Kim JH, Mun YJ, Im SJ, Han JH, Lee HS, et al.: Effects of the aqueous extract of epimedii herba on the antibody responses in mice. Int Immunopharmacol 1, 935-944, 2001.
18. Liu JJ, Li SP, and Wang YT: Optimization for quantitative determination of four flavonoids in Epimedium by capillary zone electrophoresis coupled with diode array detection using central composite design. J Chromatogr A 1103, 344-349, 2006.
19. He W, Sun H, Yang B, Zhang D, and Kabelitz D: Immunoregulatory effects of the herba Epimediia glycoside icariin. Arzneimittelforschung 45, 910-913, 1995.
20. Huang X, Zhu D, and Lou Y: Anovel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur J Pharmacol 564, 26-36, 2007.
21. Lee KS, Lee HJ, Ahn KS, Kim SH, Nam D, et al.: Cyclooxygenase- 2/prostaglandin E2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells. Cancer Lett 280, 93-100, 2009.
22. Choi HJ, Eun JS, Kim DK, Li RH, Shin TY, et al.: Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells. Eur J Pharmacol 579, 58-65, 2008.
23. Park JS, Park HY, Rho HS, Ahn S, Kim DH, et al.: Statistically designed enzymatic hydrolysis for optimized production of icariside II as a novel melanogenesis inhibitor. J Microbiol Biotechnol 18, 110-117, 2008.
24. Xia Q, Xu D, Huang Z, Liu J, Wang X, et al.: Preparation of icariside II from icariin by enzymatic hydrolysis method. Fitoterapia 81, 437-442, 2010.
25. Xing JZ, Zhu L, Jackson JA, Gabos S, Sun XJ, et al.: Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 18, 154-161, 2005.
26. Zaghloul EM, Viola JR, Zuber G, Smith CI, and Lundin KE: Formulation and delivery of splice-correction antisense oligonucleotides by amino acid modified polyethylenimine. Mol Pharm 7, 652-663, 2010.
27. Yang YL and Li XM: The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 10, 169-177, 2000.
28. Schimmer AD: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64, 7183-7190, 2004.
29. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, et al.: Main roads to melanoma. J Transl Med 7, 86, 2009.
30. Krasilnikov M, Ivanov VN, Dong J, and Ronai Z: ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22, 4092-4101, 2003.
31. Huang WL, Yeh HH, Lin CC, Lai WW, Chang JY, et al.: Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Mol Cancer 9, 309, 2010.
32. Dhawan P, Singh AB, Ellis DL, and Richmond A: Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappa B and tumor progression. Cancer Res 62, 7335-7342, 2002.
33. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC: Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63, 230-235, 2003.
34. Zaffaroni N and Daidone MG: Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 5, 65-72, 2002.
35. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, et al.: Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8, 3728-3733, 2002.
36. Dhawan P and Richmond A: A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 277, 7920-7928, 2002.
37. Kortylewski M, Jove R, and Yu H: Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 24, 315-327, 2005.
38. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, et al.: Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15, 7538-7546, 2009.